Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actinic Keratosis
Graceway Pharmaceuticals Reports Study in British Journal of Dermatology: Patients Treated with ALDARA Experienced Higher Levels of Histological and Sustained Clearance for Actinic Keratosis (AK) than Patients in two Other
May 4th, 2008
Graceway Pharmaceuticals, LLC announced the results from a study comparing 3 different treatments for actinic keratosis, a skin condition that can become cancerous if left untreated. This study evaluated three common treatment options: imiquimod 5% cream (ALDARA), topical 5-fluorouracil (5-FU), and cryotherapy. The results of this study demonstrated that patients treated with ALDARA experienced the highest level of histological (biopsy confirmed) clearance among patients in the three treatment arms. In addition, 12 months after treatment, significantly more patients remained disease free with ALDARA than after treatment with cryotherapy or 5-FU. The design and detailed results of this...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
